Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Motor delay and Delayed speech and language development; and very common findings: Cerebellar vermis hypoplasia and Micrognathia. 34 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 4 | Cleft earlobe, High palate, Macrocephaly |
MAN2C1 encodes mannosidase alpha class 2C member 1 (1,040 aa). Cleaves alpha 1,2-, alpha 1,3-, and alpha 1,6-linked mannose residues on cytoplasmic free oligosaccharides generated by N-glycoprotein degradation pathways Highest expression in Thyroid (169.5 TPM) and Ovary (152.6 TPM).
Congenital disorder of deglycosylation 2 has been associated with mutations in the MAN2C1 gene on chromosome 15.
The MAN2C1 protein participates in MAN2C1 hydrolyses GlcNAc (Man)9 to GlcNAc (Man)5 and ENGASE hydrolyses unfolded protein:(GlcNAc)2 (Man(9-5) pathways.
MAN2C1 is classified as a druggable target (Druggable Genome category) with score 0.0.
Genetic testing for MAN2C1 is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for congenital disorder of deglycosylation 2 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 2 very common features, 13 common features.
No clinical trials have been registered for congenital disorder of deglycosylation 2.
7 publications have been identified in PubMed for congenital disorder of deglycosylation 2. Research spans Basic Science / Preclinical (29%), Diagnostic / Biomarker (14%), and Review / Meta-Analysis (14%).
Aguirre-Guillen RL (2026). [PMID: 41623318](https://pubmed.ncbi.nlm.nih.gov/41623318/). *Mol Genet Metab Rep*. [Case Report / Case Series]
Kamata Y (2026). [PMID: 41687896](https://pubmed.ncbi.nlm.nih.gov/41687896/). *Bioorg Med Chem Lett*. [Basic Science / Preclinical]
Zhu L (2025). [PMID: 40687377](https://pubmed.ncbi.nlm.nih.gov/40687377/). *Mol Ther Methods Clin Dev*. [Clinical Trial Publication]
Fujihira H (2025). [PMID: 40730667](https://pubmed.ncbi.nlm.nih.gov/40730667/). *J Hum Genet*. [Review / Meta-Analysis]
Du A (2024). [PMID: 39137042](https://pubmed.ncbi.nlm.nih.gov/39137042/). *JCI Insight*. [Gene Therapy / Novel Therapeutics]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 6:12 PM UTC
Online Mendelian Inheritance in Man
Common questions about congenital disorder of deglycosylation 2
4 |
Enlarged brain ventricles (ventriculomegaly), Intellectual disability, Difficulty swallowing (dysphagia) |
Ears | 1 | Hearing loss (hearing impairment) |
Eyes | 1 | Retinal coloboma |
Muscles | 1 | Low muscle tone (hypotonia) |
Arms and legs | 1 | Ulnar deviation of the hand |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
Satoh T (2024). [PMID: 39171510](https://pubmed.ncbi.nlm.nih.gov/39171510/). *FEBS Lett*. [Basic Science / Preclinical]